Real-world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non-muscle invasive bladder cancer-Implications for global shortage [0.03%]
卡介苗（莫斯科株）膀胱内灌注治疗非肌层浸润性膀胱癌的现实世界疗效及不良反应-对全球范围内卡介苗短缺问题的思考
Amandeep Arora,Sugam Godse,Mahendra Pal et al.
Amandeep Arora et al.
High-grade recurrence-free survival (HGRFS) was defined as any relapse of high-grade (HG) urothelial cancer or carcinoma in situ (CIS). The primary outcome was to determine the HGRFS for those with originally HG disease.
Biomarker analysis and treatment dynamics following preoperative ipilimumab plus nivolumab in locally advanced urothelial cancer from the phase 1B NABUCCO study [0.03%]
NABUCCO研究中局部晚期尿路上皮癌新辅助伊匹木单抗联合纳武利尤单抗的生物标志物分析及治疗动态研究
Chantal F Stockem,Alberto Gil-Jimenez,Hamza Ali et al.
Chantal F Stockem et al.
Purpose: In NABUCCO, safety and efficacy of preoperative ipilimumab plus nivolumab were assessed in stage III urothelial cancer. Encouraging responses were achieved and ipilimumab 3 mg/kg (ipilimumab-high) appeared more e...
Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins [0.03%]
微卫星不稳定型上尿路尿路上皮癌的临床病理特征分析
Go Kobayashi,Tetsutaro Hayashi,Yohei Sekino et al.
Go Kobayashi et al.
Objectives: Lynch syndrome (LS) is an inherited cancer predisposition caused by germline mutations in DNA mismatch repair (MMR) genes. Upper tract urothelial carcinoma (UTUC) is the third most common cancer associated wit...
Recent advances in understanding the role of sex hormone receptors in urothelial cancer [0.03%]
尿路上皮癌中性激素受体作用的最新研究进展
Mohammad Amin Elahi Najafi,Takuo Matsukawa,Hiroshi Miyamoto
Mohammad Amin Elahi Najafi
This article focuses on summarizing the recent progress on understanding the role of sex hormones and their receptors in urothelial tumorigenesis, urothelial cancer progression, and resistance to non-surgical therapy for bladder cancer.
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study [0.03%]
Erdafitinib与化疗在抗程序性死亡-配体1治疗后进展的FGF受体改变的晚期或转移性尿路上皮癌中的比较：THOR三期研究中亚洲亚群的探索性分析
Nobuaki Matsubara,Yohann Loriot,Earle F Burgess et al.
Nobuaki Matsubara et al.
Introduction: The randomized phase 3 THOR study showed significantly longer survival with erdafitinib (pan-fibroblast growth factor receptor [FGFR] inhibitor) over chemotherapy in adults with FGFR-altered locally advanced or metastatic urothelial cancer (la/mUC) who had progressed
Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells [0.03%]
功能性抗氧化剂对γδT细胞增殖及其对膀胱癌细胞的细胞毒效应的影响
Yueh Pan,Hung-Jen Shih,Shu-Han Chuang et al.
Yueh Pan et al.
Notably, urothelial cancer is a sex-specific malignancy with high mortality rates worldwide.
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study [0.03%]
恩Fortumab Vedotin加派姆单抗与化疗治疗局部晚期或转移性尿路上皮癌患者的患者报告结果：一项开放标签、随机对照的III期试验（EV-302）
Shilpa Gupta,Yohann Loriot,Michiel S Van der Heijden et al.
Shilpa Gupta et al.
The dual primary endpoints of progression-free survival and overall survival in patients with locally advanced or metastatic urothelial cancer have been reported previously.
Clinical Trial
The Lancet. Oncology. 2025 Jun;26(6):795-805. DOI:10.1016/S1470-2045(25)00158-5 2025
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer [0.03%]
帕博利珠单抗治疗局部晚期或转移性尿路上皮癌二线或三线疗效分析
Tomohiro Matsuo,Yasuyoshi Miyata,Junki Harada et al.
Tomohiro Matsuo et al.
Background/aim: Pembrolizumab is widely used as second-line (2L) chemotherapy for unresectable advanced urothelial carcinoma (UC). While its anticancer effects are known, survival data, particularly on metastatic status, ...
耗时 0.21306 秒，为您在
48206918
条记录里面共找到 2994 篇文章 [XML]